TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Plasma levels of cytokines (IFN‐γ, IL‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8, IL‐10, IL‐12p70, TNF‐α, TNF‐β)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in mean number of drinks in the past 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in 28-day binge episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in rates of driving after drinking more than 3 drinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation Difficulty Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for glottic visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngoscopic view (percentage of glottic opening and modified Cormack‐Lehane grading)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF antioxidant reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F2-isoprostane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRV parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of ulcers healed in 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average time to healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain freedom at 2 h postdose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Vaccine coverage for younger adolescents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuations
Endpoint domain: Adverse events/effects
Primary endpoint: Objective measurements for clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Asthma Score (CAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Expiratory Flow Rate (PEFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Killing capacity of PMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: antianginal effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: indirect hernia sac dissection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone density increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak GH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean middle-ear pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean hearing thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy content of almonds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival curves
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of Tl-201 in low grade NHL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Ga-67 in intermediate and high grade NHL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urogenital dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FEV(1) difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Detection rate of malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of HCU compared to TTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma ACT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ClB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSS scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic prescribing rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of subjects losing more than 5% of initial weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects losing more than 10% of initial weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival probability at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Average number of cigarettes smoked per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced SSI rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decreased morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in apnea-hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in tongue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of skin disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: moderate or severe bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Length of Abstinence (LDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of EtG-negative samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GLP-1 cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean duration of maintenance of sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Actuarial event-free rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Local recurrence at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Mood scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PBF perfusion units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Permanent discontinuation of therapy due to adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Handgrip strength endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroop task accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paracetamol clearance (CLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐8 h) and AUC(0‐∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total ADHD symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAARS‐INV ratings improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrical thresholds (250 Hz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of myopia progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Tsui score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lipoprotein(a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of aortic valve stenosis and myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: overall disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal recovery of BB-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Student performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Student perception of digital lectures
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Progression-Free Survival 2 (PFS2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival 3 (PFS3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean rAFS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chest tube duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cost saving per patient
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Cerebral glucose transport reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anti-HSP60 IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in settling and night waking problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: cost of propofol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Need for intubation <72 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion to anti-HBs positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of microleakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of PVCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: text-reported PrEP adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from AF recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in NT-pro-BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in LAV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with controlled IOP at 1200 and 2000 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of controlling nighttime IOP values >18 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful CPR demonstration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: static balance ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first time to get out of bed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of renal protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Levels of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Average improvement in test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of participants attending screening appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sum of tender and swollen joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total DAS28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ultrasound score (US-7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rates of substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for additional propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate (HR) values after induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory Rate (RR) values after induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Stimulated and unstimulated salivary flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Candida counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without moderate and severe diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients without very severe diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AST and ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Albumin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Failure Free Survival (FFS)
Endpoint domain: Mortality/survival
Primary endpoint: Relapse Rates
Endpoint domain: Mortality/survival
Primary endpoint: Fat mass reduction in upper limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat mass reduction in lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lean mass change in lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean duration for dentin bridge formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thickness of dentin bridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tooth discoloration
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of bloating, indigestion, and eructation
Endpoint domain: Adverse events/effects
Primary endpoint: Forward lean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCC change at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: rectal temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin heat conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sweating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major adverse cardiac events (MACEs)
Endpoint domain: Adverse events/effects
Primary endpoint: probing reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: long-term recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of malignant neoplasms
Endpoint domain: Mortality/survival
Primary endpoint: incidence of cardiovascular disease
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decrease in KYN concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Likelihood for live birth (LB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: drivers' ability to accommodate distractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrement in performance due to distraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary event rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: adequate relief of IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical response to DC-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBeAg negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in HBV-DNA copies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to MPH in classroom attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to MPH in behavioral disinhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of academic performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: small-letter contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: large-letter contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: self-reported pain changes
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prevalence of SBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of anticoagulation control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for suturing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximal exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient compliance based on consumption of cleansing agent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: maximum change in cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Impact of ethnicity misclassification on cardiovascular risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved stability (root‐mean‐square values of anteroposterior platform torque)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fell less frequently
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stood longer on one leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophilic inflammation suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median percentage reduction in seizure frequency/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Significant hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional balance state of bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sperm deformity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: multi-site pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3/4/5 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Lead fracture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volume decrease of the swelling limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of CRC
Endpoint domain: Mortality/survival
Primary endpoint: Termination of PSVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baroreflex sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta-adrenergic sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of appearance of glycerol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: self-efficacy with regard to the disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence or levels of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TGFbeta1 levels in follicle fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: LH levels in follicle fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: EBV viral load suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonfatal ischemic stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Transient ischemic attack (TIA)
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity for the inferior visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: amount of asymmetry with eccentricity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: temporonasal field asymmetry at eccentric points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difficulty returning to sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indexes of hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes